Q-omics provides the consensus-scored ZNF209P profile across patient tissues and cancer cell-line models. ZNF209P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZNF209P is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, ZNF209P RNA expression shows 13,343 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRP, and GBM as cancer lineages where ZNF209P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF209P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF209P survival associations across molecular data types. ZNF209P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF209P RNA expression–survival associations across cancer types. High ZNF209P expression shows unfavorable associations in UCEC, CESC, READ and HNSC, but favorable associations in OV and THYM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ZNF209P RNA expression.
This table summarizes ZNF209P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF209P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF209P shows lower tumor expression in KIRP, KICH, KIRC, THCA, BRCA and PRAD. The KIRP box plot shows higher ZNF209P RNA expression in normal versus tumor tissue (log2 FC = −1.101, t-test p < 0.001).
This table shows molecular features associated with ZNF209P in patient tissues and cancer cell lines. In patient samples, ZNF209P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
